It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
HOME > BUSINESS
BUSINESS
- EA Pharma Grabs Japan Rights to Dr. Falk’s Liver Therapy
February 20, 2019
- Suzuken, Toho to Set Up Generic JV, Share Systems in Specialty Pharma Business
February 20, 2019
- Shionogi, FunPep Link to Joint Research for Antibody-Inducing Peptides in Pain Field
February 19, 2019
- Taiyo Forms Capital Alliance with Regenerative Medicine Biotech
February 19, 2019
- As Japan Goes Digital on Package Inserts, Distributors Fret Proposed Paper-Based Rule on “1st Delivery”
February 18, 2019
- Crysvita Shows Long-Term Benefits in Pediatric XLH Study
February 18, 2019
- Shire’s Product Sales Up 3.9% in 2018: Takeda
February 18, 2019
- Asahi Kasei Pharma Sets Up New Firm for Teribone Authorized Generic
February 18, 2019
- Toa, Nipro, Nihon Generic Codeveloped Symbicort Copies, Launch Timing Unclear
February 18, 2019
- Merck Serono Japan to Be Renamed “Merck Biopharma” in April
February 18, 2019
- Rexulti Misses Primary Goal in Global PIII for Bipolar I Disorder: Otsuka, Lundbeck
February 18, 2019
- Ohara Licenses Novel Glioma Treatment from US Pharma Aiming to Bolster Pediatric Pipelines
February 18, 2019
- Mitsubishi Tanabe to Begin Clinical Study in US for c-Met Targeting ADC
February 15, 2019
- Ohara’s High-Need Pediatric Cancer Drug in Limbo 2 Years after Approval due to GMP Issue
February 15, 2019
- Kowa to Reshuffle Pharma Business in April, Launching New Company for LLP Operations
February 15, 2019
- Armed with Positive Data, G47Δ Could Reach Filing in May as Japan’s 1st Oncolytic Virus
February 14, 2019
- Recordati Ratcheting Up Japan Biz, Set to Enrich Rare Disease Portfolio
February 14, 2019
- Upbeat Global Brands Drive Otsuka Sales in 2018
February 14, 2019
- GSK Japan’s Fauchet Bows Out as Chairman
February 14, 2019
- Avanir, DOJ Reach Agreement over Nuedexta Marketing Activity Case
February 14, 2019
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…